Astrocytoma Pipeline Analysis Report 2026

Report Coverage

The Astrocytoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into astrocytoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for astrocytoma. The astrocytoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The astrocytoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with astrocytoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to astrocytoma.

Read more about this report - Request a Free Sample

Astrocytoma Pipeline Outlook

Astrocytoma is a type of primary brain tumor arising from astrocytes, with grades ranging from low‑grade to highly aggressive glioblastomas. Disease management and prognosis vary widely depending on tumor grade, molecular profile, and anatomical location.

Astrocytoma treatment traditionally involves surgical resection, often followed by radiotherapy and chemotherapy based on tumor grade and resectability. In a major advancement in August 2024, vorasidenib (Voranigo) received approval from the U.S. Food and Drug Administration for the treatment of Grade 2 astrocytoma and oligodendroglioma harboring susceptible IDH1 or IDH2 mutations following surgery. This approval marked the first systemic targeted therapy for these tumors, demonstrating significantly prolonged progression-free survival compared with placebo and signaling a shift toward mutation-guided, precision-based treatment approaches in astrocytoma care.

Astrocytoma Epidemiology

Astrocytomas represent a significant subset of primary brain and spinal cord tumors in the United States. According to the American Cancer Society, approximately 25,400 malignant CNS tumors will be diagnosed in 2024, with around 18,760 deaths anticipated. The annual incidence of glioma is 6.0 per 100,000 population, with 18.8% classified as non-glioblastoma astrocytomas, highlighting their contribution to overall glioma burden. Analysis of the CBTRUS 2019 data shows that 19% of adult-type diffuse gliomas were IDH1-mutant astrocytomas. Brain and other nervous system tumors remain the leading cause of cancer death in children and adolescents under 20, emphasizing the clinical relevance of astrocytomas.

Astrocytoma – Pipeline Therapeutic Assessment

Astrocytoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total astrocytoma clinical trials. Overall, 44% of trials are in phase II, followed by 43% in phase I, 7% in phase III, This distribution highlights the current focus on early and mid-stage clinical development for novel astrocytoma therapies.

Astrocytoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the astrocytoma pipeline analysis include antibody, immunotherapy, monoclonal antibody, peptides, small molecule. The astrocytoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for astrocytoma. For instance, in October 2025, the MB-101 IL‑13Rα2–targeted CAR T‑cell therapy received U.S. FDA orphan drug designation for recurrent diffuse and anaplastic astrocytoma and glioblastoma. This status provides development incentives, including trial-cost credits and post-approval market exclusivity for these rare brain tumors.

Astrocytoma Clinical Trials – Key Players

The EMR report for the astrocytoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed astrocytoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in astrocytoma clinical trials:

• Oblato, Inc.
• Debiopharm International SA
• Neonc Technologies, Inc.
• University of Nebraska
• University of Alabama at Birmingham
• Jazz Pharmaceuticals
• M.D. Anderson Cancer Center
• Novartis

Astrocytoma – Emerging Drugs Profile

Key Questions Answered in the Astrocytoma Pipeline Insight Report

• Which companies/institutions are leading the astrocytoma drug development?
• What is the efficacy and safety profile of astrocytoma pipeline drugs?
• Which company is leading the astrocytoma pipeline development activities?
• What is the current astrocytoma commercial assessment?
• What are the opportunities and challenges present in the astrocytoma pipeline landscape?
• What is the efficacy and safety profile of astrocytoma pipeline drugs?
• Which company is conducting major trials for astrocytoma drugs?
• Which companies/institutions are involved in astrocytoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in astrocytoma?

Reasons To Buy This Report

The Astrocytoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for astrocytoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into astrocytoma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Brain Tumor Treatment Market

Pediatric Brain Tumors Drug Pipeline Analysis Report

Brain Cancer Epidemiology Forecast